15 mg Mirtazapine Orally Disintegrating Tablets, Non-Fasting
Condition: Healthy
Intervention: Mirtazapine 15 mg (Orally Disintegrating) Tablets; REMERON SolTab® 15 mg Orally Disintegrating Tablets
Intervention description: 1 x 15 mg, single-dose non-fasting; 1 x 15 mg, single-dose non-fasting
Intervention MeSH terms: Mirtazapine
Phase: Phase 1
Study type: Interventional
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Enrollment: 32.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Bioequivalence; Healthy Subjects

Summary:

      This study will compare the relative bioavailability (rate and extent of absorption) of 15 mg
      Mirtazapine (Orally Disintegrating) Tablets manufactured by TEVA Pharmaceutical Industries,
      Ltd.; distributed by TEVA Pharmaceuticals USA with that of 15 mg REMERON SolTab® Orally
      Disintegrating Tablets manufactured for Organon Inc. by CIMA Labs Inc. following a single
      oral dose (1 x 15 mg) in healthy adult subjects under non-fasting conditions.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Screening Demographics: All subjects selected for this study will be healthy men or
             women 18 years of age or older at the time of dosing. The subject's body mass index
             (BMI) should be less than or equal to 30.

          -  Screening Procedures: Each subject will complete the screening process within 28 days
             prior to Period I dosing. Consent documents for both the screening evaluation and HIV
             antibody determination will be reviewed, discussed, and signed by each potential
             participant before fill implementation of screening procedures.

          -  Screening will include general observations, physical examination, demographics,
             medical and medication history, an electrocardiogram, sitting blood pressure and heart
             rate, respiratory rate and temperature. The physical examination will include, but may
             not be limited to, an evaluation of the cardiovascular, gastrointestinal, respiratory
             and central nervous systems.

          -  The screening clinical laboratory will include:

               -  Hematology: hematocrit, hemoglobin, WBC count with differential, RBC count,
                  platelet count;

               -  Clinical Chemistry: serum creatinine, BUN, glucose, AST(GOT), ALT(GPT), albumin,
                  total bilirubin, total protein, and alkaline phosphatase;

               -  HIV antibody, hepatitis B surface antigen, and hepatitis C antibody screens;

               -  Urinalysis: by dipstick; full microscopic examination of dipstick positive; and

               -  Urine Drug Screen: ethyl alcohol, amphetamines, barbiturates, benzodiazepines,
                  cannabinoids, cocaine metabolites, opiates and phencyclidine.

               -  Serum Pregnancy Screen (female subjects only)

          -  If female and:

               -  of childbearing potential, is practicing an acceptable barrier method of birth
                  control for the duration of the study as judged by the investigator(s), such as
                  condoms, sponge, foams, jellies, diaphragm, intrauterine device (IUD), or
                  abstinence; or

               -  is postmenopausal for at least 1 year; or

               -  is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
                  hysterectomy).

        Exclusion Criteria:

          -  Subjects with a recent history of drug or alcohol addiction or abuse.

          -  Subjects with the presence of a clinically significant disorder involving the
             cardiovascular, respiratory, gastrointestinal, immunologic, hematologic, endocrine, or
             neurologic system(s) or psychiatric disease (as determined by the clinical
             investigators).

          -  Subjects whose clinical laboratory test values are outside the accepted reference
             range and when confirmed on re-examination are deemed to be clinically significant.

          -  Subjects demonstrating a positive hepatitis B surface antigen screen, hepatitis C
             antibody screen, or a reactive HIV antibody screen.

          -  Subjects demonstrating a positive pregnancy screen.

          -  Subjects who are currently breastfeeding.

          -  Subjects with a history of clinically significant allergies including drug allergies.

          -  Subjects with a history of allergic response(s) to mirtazapine or related drugs.

          -  Subjects with a clinically significant illness during the 4 weeks prior to Period I
             dosing (as determined by the clinical investigators).

          -  Subjects who currently use of have used tobacco products within 90 days of Period I
             dosing.

          -  Subjects who have taken any drug known to induce or inhibit hepatic drug metabolism in
             the 28 days prior to Period I dosing.

          -  Subjects who report donating greater than 150 mL of blood within 28 days prior to
             Period I dosing. All subjects will be advised not to donate blood for four weeks after
             completing the study.

          -  Subjects who have donated plasma (e.g. plasmapheresis) within 14 days prior to Period
             I dosing. All subjects will be advised not to donate plasma for four weeks after
             completing the study.

          -  Subjects who report receiving any investigational drug within 28 days prior to Period
             I dosing.

          -  Subjects who report taking any systemic prescription medication in the 14 days prior
             to Period I dosing.

          -  Subjects who report an intolerance of direct venipuncture.

          -  Subjects who report consuming an abnormal diet during the 28 days prior to Period I
             dosing.